 |
|
Alprazolam Kinetics in the ElderlyRelation to Antipyrine Disposition
David J. Greenblatt, MD;
Marcia Divoll;
Darrell R. Abernethy, MD, PhD;
Lawrence J. Moschitto, MD;
Randall B. Smith, PhD;
Richard I. Shader, MD
Arch Gen Psychiatry. 1983;40(3):287-290.
Abstract
• The pharmacokinetics of alprazolam, a triazolobenzodiazepine anxiolytic-antidepressant, were assessed in 32 healthy men and women aged 21 to 78 years after a single 1.0-mg oral dose. Peak alprazolam levels averaged 20.4 ng/mL and were reached a mean of 1.25 hours after dosage. Mean elimination half-life did not differ significantly between elderly and young women, nor did total metabolic clearance. However, half-life was significantly prolonged, and total clearance significantly reduced, in elderly v young men. Antipyrine oxidizing capacity was also evaluated, and half-life for the two drugs was highly correlated, as were their metabolic clearances. Thus, old age is associated with impaired capacity to oxidize alprazolam, but this effect is far more apparent in men than in women. A test of antipyrine half-life and clearance may help identify slow or rapid metabolizers of alprazolam.
Author Affiliations
From the Division of Clinical Pharmacology, Departments of Psychiatry and Medicine, Tufts University School of Medicine and New England Medical Center Hospital, Boston (Drs Greenblatt, Abernethy, Moschitto, and Shader and Ms Divoll); and the Medical Bioavailability Unit, The Upjohn Co, Kalamazoo, Mich (Dr Smith).
Footnotes
Accepted for publication Dec 31, 1981.
Reprint requests to Division of Clinical Pharmacology, Box 1007, New England Medical Center Hospital, 171 Harrison Ave, Boston, MA 02111 (Dr Greenblatt).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Age-Related Differences in CYP3A Expression and Activity in the Rat Liver, Intestine, and Kidney
Warrington et al.
J. Pharmacol. Exp. Ther. 2004;309:720-729.
ABSTRACT
| FULL TEXT
Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes
Patki et al.
J. Pharmacol. Exp. Ther. 2004;308:874-879.
ABSTRACT
| FULL TEXT
Comparative Kinetics and Response to the Benzodiazepine Agonists Triazolam and Zolpidem: Evaluation of Sex-Dependent Differences
Greenblatt et al.
J. Pharmacol. Exp. Ther. 2000;293:435-443.
ABSTRACT
| FULL TEXT
Effects of Age on In Vitro Midazolam Biotransformation in Male CD-1 Mouse Liver Microsomes
Warrington et al.
J. Pharmacol. Exp. Ther. 2000;292:1024-1031.
ABSTRACT
| FULL TEXT
Plasma Alprazolam Concentrations: Relation to Efficacy and Side Effects in the Treatment of Panic Disorder
Greenblatt et al.
Arch Gen Psychiatry 1993;50:715-722.
ABSTRACT
|
